Novo Nordisk's Oral Wegovy Sees Strong Early Demand Following January Launch

Novo Nordisk has reported a significant surge in demand for the oral version of its weight-loss drug, Wegovy, following its official launch in January 2026. The pill achieved strong market uptake within its first month, reflecting a growing preference for oral alternatives to traditional injectable treatments. Data indicates a sharp rise in awareness and prescribing rates among both primary care physicians and endocrinologists. This rapid adoption underscores the high market potential for oral GLP-1 therapies in the competitive obesity treatment sector. Analysts view this successful rollout as a positive catalyst for the company's stock performance. The strong initial performance reinforces Novo Nordisk's leadership position in the global metabolic health market.